Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
The study is being conducted to evaluate the efficacy, safety and tolerability of chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
DRUG: Apatinib 250mg|DRUG: Camrelizumab|DRUG: S-1, Oxaliplatin|DRUG: Apatinib 500mg
Pathological Complete Response (pCR), Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment|Event-free Survival (EFS), Up to approximately 2 years
Major pathological response(MPR), Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment|Margin-free (R0) resection rate, Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment|DFS, up to 2 years|OS, up to 3 years|Downstaging of N stage, Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment|AEs, Up to approximately 18 months
The study is being conducted to evaluate the efficacy, safety and tolerability of chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.